Moderna (MRNA) Stock Forecast, Price & News

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View MRNA analyst ratings or view top-rated stocks.

14 analysts have issued 1-year target prices for Moderna's shares. Their MRNA share price forecasts range from $93.00 to $296.00. On average, they anticipate the company's share price to reach $179.13 in the next year. This suggests a possible upside of 41.6% from the stock's current price.
View analysts price targets for MRNA or view top-rated stocks among Wall Street analysts.

Moderna's stock was trading at $179.62 at the start of the year. Since then, MRNA shares have decreased by 29.6% and is now trading at $126.54.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our MRNA earnings forecast.

Moderna, Inc. (NASDAQ:MRNA) issued its quarterly earnings data on Thursday, May, 4th. The company reported $0.19 earnings per share for the quarter, topping analysts' consensus estimates of ($1.77) by $1.96. The company earned $1.86 billion during the quarter, compared to analyst estimates of $1.17 billion. Moderna had a trailing twelve-month return on equity of 25.87% and a net margin of 31.77%. The business's quarterly revenue was down 69.3% on a year-over-year basis. During the same period in the prior year, the business earned $8.58 EPS.

ETFs with the largest weight of Moderna (NASDAQ:MRNA) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), Direxion mRNA ETF (MSGR), Invesco Nasdaq Biotechnology ETF (IBBQ), VanEck Biotech ETF (BBH), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB), iShares Genomics Immunology and Healthcare ETF (IDNA) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

(MRNA) raised $499 million in an initial public offering on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Moderna trades on the NASDAQ under the ticker symbol "MRNA."

Moderna's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (12.03%), BlackRock Inc. (6.58%), State Street Corp (3.69%), Geode Capital Management LLC (1.64%), Wellington Management Group LLP (1.13%) and FMR LLC (1.04%). Insiders that own company stock include David W Meline, Dustin A Moskovitz, Elizabeth G Nabel, Juan Andres, Lori M Henderson, Lori M Henderson, Lori M Henderson, Mark D Mclaughlin, Noubar Afeyan, Paul Sagan, Shannon Thyme Klinger, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and W Don Cornwell.
View institutional ownership trends.

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRNA stock can currently be purchased for approximately $126.54.

Moderna (NASDAQ:MRNA) has a market capitalization of $48.24 billion and generates $19.26 billion in revenue each year. The company earns $8.36 billion in net income (profit) each year or $11.57 on an earnings per share basis.

The company employs 3,900 workers across the globe.

Moderna's mailing address is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for the company is www.modernatx.com. The company can be reached via phone at (617) 714-6500 or via email at ir@modernatx.com.